Daily, Thu 12 Nov: A Shanghai pill wins FDA approval, after China said yes first
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
Basil Lui (linkedin.com/in/basillui) and Ning discuss Abbisko's pimicotinib (Pimjetmi), FDA-approved for tenosynovial giant cell tumour after China, Canada and Switzerland, on a trial with almost half its patients in China; the FDA's Saturday date for Akeso and Summit's ivonescimab in EGFR-mutated lung cancer; Korea allowing GLP-1 drugs bought abroad; and Windward Bio's Nasdaq IPO built on antibodies from Kelun-Biotech, Harbour BioMed and Qyuns. ImvivaBio's off-the-shelf CAR-T CTA313 reports 12-month lupus data from Phase 1 work in China, and Shionogi licenses cefiderocol to Singapore-based Link Healthcare. Also: Neuralink's PRIME 2 adds stroke; a Chinese all-day EEG electrode; Korea's RayWatt.
Full transcript and all sources for this episode
Both voices are AI-cloned. Basil Lui is the real person behind the show; Ning is an AI co-host. Personal views, not investment or medical advice.
Chapters
0:00 Intro and AI-voice disclosure
0:51 Abbisko's pimicotinib, China then US
3:30 Akeso and Summit's ivonescimab date
4:54 Korea lets in GLP-1 drugs bought abroad
6:06 Windward Bio's IPO, Chinese antibodies
7:28 CTA313: off-the-shelf CAR-T for lupus
8:54 Shionogi's cefiderocol and Singapore
9:51 Neuralink's PRIME 2 adds stroke
11:10 Beyond biotech: EEG gel and RayWatt
12:37 What to watch and sign-off
Key sources: US FDA: pimicotinib approval · Summit Q3 2026 (company release) · ImvivaBio: CTA313 at ACR (company press release) · Shionogi: cefiderocol licence (company press release)
Weekly LinkedIn newsletter
Also listen on: Apple Podcasts · Amazon Music · YouTube